Seeing Is Believing
Currently out of the existing stock ratings of Sumant Kulkarni, 119 are a BUY (86.86%), 18 are a HOLD (13.14%).
Analyst Sumant Kulkarni, currently employed at CANACCORD, carries an average stock price target met ratio of 32.76% that have a potential upside of 35.17% achieved within 187 days.
Sumant Kulkarni’s has documented 279 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on VYGR, Voyager Therapeutics at 14-Nov-2024.
Analyst best performing recommendations are on CRTX (CORTEXYME).
The best stock recommendation documented was for CRTX (CORTEXYME) at 6/3/2019. The price target of $42 was fulfilled within 15 days with a profit of $17.87 (74.06%) receiving and performance score of 49.37.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$27
$10.58 (64.43%)
$27
13 days ago
(07-Nov-2024)
8/22 (36.36%)
$9.79 (56.89%)
119
Buy
$28
$11.58 (70.52%)
$28
13 days ago
(07-Nov-2024)
0/4 (0%)
$10.79 (62.70%)
Hold
1 months 10 days ago
(10-Oct-2024)
11/14 (78.57%)
$9.98 (39.89%)
141
Buy
$23
$6.58 (40.07%)
$30
3 months 12 days ago
(08-Aug-2024)
0/3 (0%)
$7.28 (46.31%)
Buy
$20
$3.58 (21.80%)
$28
3 months 13 days ago
(07-Aug-2024)
16/21 (76.19%)
$4.83 (31.84%)
184
Which stock is Sumant Kulkarni is most bullish on?
Which stock is Sumant Kulkarni is most reserved on?
What Year was the first public recommendation made by Sumant Kulkarni?